7Baggers
 Published on: 2025-10-03 01:27:08  newser.com Fri, 03 Oct 2025 06:27:08 GMT
 published on: 2025-10-02 21:59:53  newser.com Fri, 03 Oct 2025 02:59:53 GMT
 Published on: 2025-10-02 20:29:11  newser.com Fri, 03 Oct 2025 01:29:11 GMT
 published on: 2025-09-29 05:42:28  newser.com Mon, 29 Sep 2025 10:42:28 GMT
 mersana therapeutics stock surges on promising clinical progress  AD HOC NEWS Sat, 27 Sep 2025 05:27:04 GMT
 Published on: 2025-09-22 12:11:46  newser.com Mon, 22 Sep 2025 17:11:46 GMT
 mersana therapeutics faces nasdaq non-compliance notice  MSN Tue, 16 Sep 2025 01:03:55 GMT
 William Blair Maintains Mersana Therapeutics(MRSN.US) With Buy Rating  富途牛牛 Mon, 15 Sep 2025 19:45:31 GMT
 mersana therapeutics faces nasdaq non-compliance notice  MSN Wed, 10 Sep 2025 12:54:22 GMT
 mersana therapeutics faces nasdaq non-compliance notice  MSN Sat, 06 Sep 2025 09:42:16 GMT
 published on: 2025-09-05 14:49:22  Newser Fri, 05 Sep 2025 19:49:22 GMT
 published on: 2025-09-05 05:23:37  Newser Fri, 05 Sep 2025 10:23:37 GMT
 Mersana Therapeutics Faces Nasdaq Non-Compliance Notice  TipRanks Fri, 05 Sep 2025 07:00:00 GMT
 published on: 2025-09-04 00:09:01  Newser Thu, 04 Sep 2025 05:09:01 GMT
 published on: 2025-09-03 23:47:16  Newser Thu, 04 Sep 2025 04:47:16 GMT
 published on: 2025-09-03 03:35:48  Newser Wed, 03 Sep 2025 08:35:48 GMT
 published on: 2025-09-02 14:54:04  Newser Tue, 02 Sep 2025 19:54:04 GMT
 mersana therapeutics' svp sells shares worth $4,912  MSN Sun, 31 Aug 2025 10:21:35 GMT
 published on: 2025-08-30 19:53:20  beatles.ru Sat, 30 Aug 2025 07:00:00 GMT
 published on: 2025-08-29 05:13:42  sundaytimes.kr Thu, 28 Aug 2025 20:14:28 GMT
 published on: 2025-08-28 02:34:23  Newser Thu, 28 Aug 2025 07:34:23 GMT
 published on: 2025-08-26 19:25:45  Newser Wed, 27 Aug 2025 00:25:45 GMT

Mersana Therapeutics, Inc
(NASDAQ:MRSN) 

MRSN stock logo

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients w...

Founded: 2001
Full Time Employees: 83
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends